U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06847867) titled 'A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome' on Feb. 21.
Brief Summary: The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial will also examine how the body processes the drug. The study is comprised of two parts: Part 1: Participants will receive different doses of momelotinib to find the best dose by evaluating effectiveness in improving red blood cell transfusion requirements and safety. Part 2: Participants will receive dose selected from Part 1 to assess its impact on improving red blood cell t...